Regenxbio (RGNX) Cash & Equivalents (2014 - 2025)

Regenxbio's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $34.5 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 40.09% year-over-year to $34.5 million; the TTM figure through Dec 2025 stood at $34.5 million (down 40.09% YoY), while the FY2025 annual figure was $34.5 million, down 40.09% from the prior year.
• Cash & Equivalents was $34.5 million for Q4 2025 at Regenxbio, down from $58.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $345.2 million in Q4 2021 to a low of $34.5 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $123.2 million across 5 years, with a median of $88.3 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents surged 319.94% in 2021, then sank 71.91% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $345.2 million in 2021, then tumbled by 71.91% to $97.0 million in 2022, then plunged by 64.39% to $34.5 million in 2023, then soared by 66.64% to $57.5 million in 2024, then plunged by 40.09% to $34.5 million in 2025.
• The last three Cash & Equivalents figures came in at $34.5 million (Q4 2025), $58.8 million (Q3 2025), and $79.6 million (Q2 2025), per Business Quant data.